MannKind Corporation - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MNKD Nasdaq 2830 mannkindcorp.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MannKind Corporation

Is MannKind Corporation (MNKD) A Good Stock To Buy Now? - Jun 29th, 2026 1:35 pm
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D - Jun 23rd, 2026 7:00 am
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” - Jun 13th, 2026 9:31 am
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data - Jun 11th, 2026 8:13 pm
Jim Cramer Says He Blessed MannKind as a Speculation Only - Jun 8th, 2026 9:34 am
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems - Jun 5th, 2026 5:35 pm
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy - Jun 5th, 2026 3:56 pm
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF - Jun 3rd, 2026 4:05 am
MannKind (MNKD) Is Up 11.5% After Afrezza Pediatric Approval And Trial Relief - Has The Bull Case Changed? - Jun 1st, 2026 2:12 am
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market - May 30th, 2026 9:07 pm
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - May 29th, 2026 1:43 pm
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval - May 29th, 2026 12:00 pm
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes - May 29th, 2026 10:30 am
MNKD Stock Eyes Best Month Since 2022 Ahead Of FDA Decision On Pediatric Diabetes Treatment - May 28th, 2026 5:19 am
MannKind to Present at Jefferies Global Healthcare Conference - May 27th, 2026 2:00 pm
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems - May 27th, 2026 7:05 am
MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M - May 17th, 2026 10:50 pm
ARKO Petroleum And 2 Other Value Stocks Priced Below Estimated Worth - May 13th, 2026 11:38 am
Wells Fargo Raises its Price Target on MannKind (MNKD) to $10 - May 13th, 2026 12:22 am
H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets - May 11th, 2026 3:21 pm